Is PT-141 (Bremelanotide) Legal in California?
Key numbers
- 1.75 mgStrength of the prescription-only Vyleesi subcutaneous autoinjector for premenopausal womenSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 6 mmHgMaximal systolic blood pressure rise after one Vyleesi dose, per the labelSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 1.9 mmHgMean daytime systolic blood pressure rise in 127 premenopausal women dosed daily for 8 daysSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 8 doses per monthMonthly Vyleesi use limit: more than this number of doses per month is not recommendedSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
See the public record for Bremelanotide
At a glance
- FDA status / Approved as Vyleesi (NDA 210557) on June 21, 2019 [1][2]
- Form / 1.75 mg subcutaneous autoinjector, used as needed [1]
- Prescription status / Prescription only [1]
- Approved use / Premenopausal women with acquired, generalized HSDD [1]
- Not approved for / Men, postmenopausal women, or enhancing sexual performance [1]
- Boxed warning / None [1]
What the FDA approval covers
Vyleesi is bremelanotide, approved June 21, 2019 under NDA 210557 and now held by Cosette Pharmaceuticals [1][2]. It is a 1.75 mg subcutaneous autoinjector, prescription only [1].
The approved use is narrow: premenopausal women with acquired, generalized HSDD, meaning low sexual desire causing marked distress or interpersonal difficulty that is not due to a co-existing medical or psychiatric condition, relationship problems, or a medication or drug [1]. The label states it is not indicated for HSDD in postmenopausal women or in men, and not to enhance sexual performance [1].
PT-141 products that are not Vyleesi
Compounded and research-use products sold as PT-141 are not Vyleesi and are not FDA-approved drugs [3][1]. FDA does not review compounded drugs for safety, effectiveness or quality before they reach patients [4].
Bremelanotide does not appear on FDA's page of bulk substances that may present significant safety risks when compounded (content dated April 22, 2026), and it is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [5][6][7]. Those facts do not make a compounded product FDA-approved.
Questions worth asking
What the label says about use and risk
The label contraindicates Vyleesi in patients with uncontrolled hypertension or known cardiovascular disease [1]. Each dose raises blood pressure briefly: the label reports maximal increases of 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with heart rate falling by up to 5 beats per minute and values usually back to baseline within 12 hours [1]. In an ambulatory study of 127 premenopausal women dosed daily for 8 days, mean daytime blood pressure rose 1.9 mmHg systolic and 1.7 mmHg diastolic [1].
The label reports that Vyleesi may slow gastric emptying and reduce absorption of oral medicines. It says to avoid Vyleesi with oral drugs that depend on threshold blood levels, such as antibiotics, and with oral naltrexone products intended to treat alcohol or opioid addiction [1].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Frequently asked questions
Is PT-141 legal in California?
Do you need a prescription for PT-141?
Is bremelanotide approved for men?
Does Vyleesi have a boxed warning or REMS?
How is Vyleesi used?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
Where can I buy PT-141?
Vyleesi is the FDA-approved form and is prescription only. Compounded or research-use products sold as PT-141 are not Vyleesi and are not FDA-approved drugs, and FDA does not review them for safety, effectiveness or quality before they reach patients.
Can PT-141 be taken orally?
The approved form is a 1.75 mg subcutaneous autoinjector, not a pill. The label says Vyleesi may slow gastric emptying and reduce absorption of oral medicines, so it advises avoiding it with oral drugs that depend on threshold blood levels, such as antibiotics, and with oral naltrexone products used for alcohol or opioid addiction.
Is PT-141 safe to take?
The label contraindicates Vyleesi in patients with uncontrolled hypertension or known cardiovascular disease. Each dose raises blood pressure briefly, with maximal increases of 6 mmHg systolic and 3 mmHg diastolic peaking 2 to 4 hours after the dose, and values usually return to baseline within 12 hours.
References
Show all 7 referencesHide references
- U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
- U.S. Food and Drug Administration. Approval letter, NDA 210557 (Vyleesi), 2019. FDA approval letter, NDA 210557
- Federal Register public inspection document 2026-22192, 2026.
- Human Drug Compounding Laws | FDA.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration. FDA bulk drug substances lists. FDA bulk drug substances document
- U.S. Department of Health and Human Services. Peptide enforcement discretion policy, Appendix B, 2026. HHS peptide enforcement discretion policy, Appendix B